[Periferal blood subpopulation and apoptosis indices in the treatment of chronic myelogenous leukemia with Imatinib].
The results of immunophenotyping investigations of periferal blood granulocyte and lymphocyte population, number of p53+ and Bcl-2+ in 57 patients (among them 18 persons suffered after the Chernobyl NPP accident) with chronic phase of chronic myelogenic leukemia were presented in the article. The reduction of CD34+ granulocytes number, normalization of CD95 cells, negative correlation between the number of CD95 and p53, Bcl-2 granulocytes in Imatinib treated patients in comparison with a control group was determined. The results of the investigation confirmed the efficiency of using BCR/ABL tyrosin kinase inhibitor Imatinib in the treatment of chronic phase of CML.
Bazyka
D A
DA
Bebeshko
V H
VH
Liubarets'
T F
TF
Diahil'
I S
IS
Il'ienko
I M
IM
Maznichenko
O L
OL
Kadnikova
T V
TV
D000328:Adult; D015703:Antigens, CD / Q000276:immunology; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects*; D001549:Benzamides; D047852:Chernobyl Nuclear Accident; D005434:Flow Cytometry; D006098:Granulocytes / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D008214:Lymphocytes / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use*; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome; D014455:Ukraine; D055815:Young Adult
D015703:Antigens, CD; D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate